Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

141. Umeclidinium/vilanterol (as trifenatate) (Anoro Ellipta) - chronic obstructive pulmonary disease (COPD)

Umeclidinium/vilanterol (as trifenatate) (Anoro Ellipta) - chronic obstructive pulmonary disease (COPD) %PDF-1.5 %���� 54 0 obj > endobj 72 0 obj >/Filter/FlateDecode/ID[ ]/Index[54 36]/Info 53 0 R/Length 87/Prev 198139/Root 55 0 R/Size 90/Type/XRef/W[1 2 1]>>stream h�bbd``b`�$�D�`�� A�l��d��2��X� V��iS ����8����p$��H%�?��%l 7 endstream endobj startxref 0 %%EOF 89 0 obj >stream h�b`````j`o�P#�0p4 � @1C��gC�N&o� ��[����4T.�r`.�e 5��A�DfA�Y, �_VCD� �i� endstream endobj 55 0 obj >/Metadata 2 0 R

All Wales Medicines Strategy Group2015

142. In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia?

In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? BestBets: In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? In patients presenting with an exacerbation of COPD can a normal venous blood gas pCO2 rule out arterial hypercarbia? Report By: Mark Woods - Consultant in Emergency Medicine Search checked by David Hodgson - ST5 Emergency Medicine Institution: Whiston (...) Hospital, Merseyside, UK and Mersey School of Emergency Medicine, UK Date Submitted: 31st August 2012 Date Completed: 10th March 2015 Last Modified: 11th March 2015 Status: Green (complete) Three Part Question In [patients with an Acute Exacerbation of COPD] can a [normal venous blood gas CO2] [rule out arterial hypercarbia]? Clinical Scenario A 74 year old male patient with known COPD presents acutely breathless with widespread wheeze. He refuses an arterial blood gas (ABG) and complains that last

BestBETS2015

143. Global Strategy for Diagnosis, Management, and Prevention of COPD

Global Strategy for Diagnosis, Management, and Prevention of COPD ');//--> Search Menu Connect With Us Search in: Title 25 Broadway New York, NY 10004 (212) 315-8600 ATS Journals Services General Information Copyright © 1987-2017 American Thoracic Society, All Rights Reserved.

European Respiratory Society2015

144. Mortality risk prediction in COPD by a prognostic biomarker panel

Mortality risk prediction in COPD by a prognostic biomarker panel 25034566 2014 12 01 2015 07 20 2015 11 19 1399-3003 44 6 2014 Dec The European respiratory journal Eur. Respir. J. Mortality risk prediction in COPD by a prognostic biomarker panel. 1557-70 10.1183/09031936.00043814 Chronic obstructive pulmonary disease (COPD) is a complex disease with various phenotypes. The simultaneous determination of multiple biomarkers reflecting different pathobiological pathways could be useful (...) in identifying individuals with an increased risk of death. We derived and validated a combination of three biomarkers (adrenomedullin, arginine vasopressin and atrial natriuretic peptide), assessed in plasma samples of 385 patients, to estimate mortality risk in stable COPD. Biomarkers were analysed in combination and defined as high or low. In the derivation cohort (n = 142), there were 73 deaths during the 5-year follow-up. Crude hazard ratios for mortality were 3.0 (95% CI 1.8-5.1) for one high biomarker

EvidenceUpdates2015

145. Olodaterol (as hydrochloride) (Striverdi Respimat) - as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD)

Olodaterol (as hydrochloride) (Striverdi Respimat) - as a maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD) %PDF-1.5 %���� 51 0 obj > endobj 69 0 obj >/Filter/FlateDecode/ID[ ]/Index[51 36]/Info 50 0 R/Length 88/Prev 197988/Root 52 0 R/Size 87/Type/XRef/W[1 2 1]>>stream h�bbd``b`�$�D�`�̕ �+�*��@�I � +HpG��) � �� ����3012I00R��ϸ�#@�� 7 endstream endobj startxref 0 %%EOF 86 0 obj >stream h�b`````j`o^0�F fa�h@�b�!φ� K�d�( pT091LbP8���p �`Vs�.c�I��k

All Wales Medicines Strategy Group2015

146. Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD

Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD Hand-held Fourier transform infrared (FTIR) spectroscopy to diagnose and monitor COPD NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Hand-held Fourier transform (...) infrared (FTIR) spectroscopy to diagnose and monitor COPD. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives The hand-held Fourier transform infrared (FTIR) spectroscopy device, developed by Glyconics Ltd., analyses the composition of sputum from patients with chronic obstructive pulmonary disease (COPD), to diagnose and monitor the disease. The device is intended to be used in the home by health professionals, as well as in primary

Health Technology Assessment (HTA) Database.2015

147. BuddyWOTCHT to monitor COPD

BuddyWOTCHT to monitor COPD BuddyWOTCH™ to monitor COPD BuddyWOTCH™ to monitor COPD NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. BuddyWOTCH™ to monitor COPD. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives BuddyWOTCH™ is a smartwatch that can be worn all the time at home (...) to monitor the health of patients with chronic obstructive pulmonary disease (COPD). It has sensors that record walking, oxygen levels in the blood, temperature and heart rate. The developer says it can detect and warn the patient of a COPD 'flare-up', so that they can access treatments quicker. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Monitoring, Physiologic; Pulmonary Disease, Chronic Obstructive Language Published English Country of organisation England

Health Technology Assessment (HTA) Database.2015

148. Randomised controlled trial: Discontinuing inhaled steroids might not be safe in severe COPD cases

Randomised controlled trial: Discontinuing inhaled steroids might not be safe in severe COPD cases Discontinuing inhaled steroids might not be safe in severe COPD cases | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Discontinuing inhaled steroids might not be safe in severe COPD cases Article Text Therapeutics/Prevention Randomised controlled trial Discontinuing inhaled steroids might not be safe in severe COPD cases Rafael Laniado-Laborín Statistics from Altmetric.com No Altmetric data available for this article. Commentary on : Magnussen H , Disse

Evidence-Based Medicine (Requires free registration)2015

149. Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis

Pulmonary Rehabilitation for Postacute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Cost-Effectiveness and Budget Impact Analysis

Health Quality Ontario2015

150. Prevention of Acute Exacerbations of COPD

Prevention of Acute Exacerbations of COPD 894 Evidence-Based Medicine [ 147#4 CHEST APRIL 2015 ] P r e v en tio n o f A c u t e Exacerba tio n s o f C O PD American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP ; Pat G. Camp (...) , PhD, PT ; Bartolome R. Celli , MD, FCCP ; Gail Dechman , PhD, PT ; Mark T. Drans? eld , MD ; Stanley B. Fiel , MD, FCCP ; Marilyn G. Foreman , MD, FCCP ; Nicola A. Hanania , MD, FCCP ; Belinda K. Ireland , MD ; Nathaniel Marchetti , DO, FCCP ; Darcy D. Marciniuk , MD, FCCP ; Richard A. Mularski , MD, MSHS, MCR, FCCP ; Joseph Ornelas , MS ; Jeremy D. Road , MD ; and Michael K. Stickland , PhD BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as well as throughout

American College of Chest Physicians2015

151. Executive Summary: Prevention of Acute Exacerbation of COPD

Executive Summary: Prevention of Acute Exacerbation of COPD 883 journal.publications.chestnet.org E x e c u t i v e S umm a r y Prevention of Acute Exacerbation of COPD: American College of Chest Physicians and Canadian Th oracic Society Guideline Gerard J. Criner , MD, FCCP ; Jean Bourbeau , MD, FCCP ; Rebecca L. Diekemper , MPH ; Daniel R. Ouellette , MD, FCCP ; Donna Goodridge , RN, PhD ; Paul Hernandez , MDCM ; Kristen Curren , MA ; Meyer S. Balter , MD, FCCP ; Mohit Bhutani , MD, FCCP (...) - 893 ABBREVIATIONS : AEC O P D 5 ac u t e exacerba tio n o f C O PD ; C D C 5 US C en t er s f o r Dis e as e C o n t r o l a n d P r e v en tio n ; CHES T 5 Amer ica n C o lleg e o f Chest Ph ysicia n s ; CT S 5 Canadian Th oracic S o ciety ; WH O 5 W o r l d H e a l t h Or ga niza tio n COPD is a common disease with substantial associated morbidity and mortality. Patients with COPD usually have a progression of airfl ow obstruction that is not fully reversible and can lead to a history of progres

American College of Chest Physicians2015

152. Umeclidinium (Incruse) - as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Umeclidinium (Incruse) - as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Scottish Medicines Consortium2014

153. Indacaterol maleate, glycopyrronium bromide (Ultibro Breezhaler) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Indacaterol maleate, glycopyrronium bromide (Ultibro Breezhaler) - maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Published 08 December 2014 Product Update: indacaterol maleate 143micrograms (equivalent to 110microgram indacaterol) with glycopyrronium bromide 63micrograms (equivalent to 50microgram glycopyrronium) inhalation powder hard capsules (Ultibro ® Breezhaler ® 85microgram/43microgram [delivered dose (...) Scotland. Indication under review: maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). For patients in whom the combination of indacaterol maleate and glycopyrronium bromide is an appropriate choice of therapy, Ultibro ® Breezhaler ® provides the two ingredients in a single hard capsule at a lower cost than the individual components. Advice context: No part of this advice may be used without the whole of the advice being quoted

Scottish Medicines Consortium2014

154. Self-care support for people with COPD

Self-care support for people with COPD Self-care support for people with COPD Self-care support for people with COPD Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Centre for Reviews and Dissemination. Self-care support for people with COPD. University of York. Evidence briefings. 2014 Authors (...) ' conclusions As the prevalence of long-term conditions increases there is a greater focus on encouraging people to manage their condition(s). Self-care has been identified as integral to maintaining the health and wellbeing of people with COPD. There is consistent evidence that multicomponent interventions reduce respiratory-related hospital admissions and improve quality of life for people with COPD. Multicomponent interventions that include action plans, exercise, education and smoking cessation

Health Technology Assessment (HTA) Database.2014

155. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. 25196117 2014 10 02 2014 10 14 2015 11 19 1533-4406 371 14 2014 Oct 02 The New England journal of medicine N. Engl. J. Med. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. 1285-94 10.1056/NEJMoa1407154 Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the (...) benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored. In this 12-month, double-blind, parallel-group study, 2485 patients with a history of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy

NEJM2014

156. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. BACKGROUND: Treatment with inhaled glucocorticoids in combination with long-acting bronchodilators is recommended in patients with frequent exacerbations of severe chronic obstructive pulmonary disease (COPD). However, the benefit of inhaled glucocorticoids in addition to two long-acting bronchodilators has not been fully explored. METHODS: In this 12-month, double-blind, parallel-group study, 2485 patients with a history (...) of exacerbation of COPD received triple therapy consisting of tiotropium (at a dose of 18 μg once daily), salmeterol (50 μg twice daily), and the inhaled glucocorticoid fluticasone propionate (500 μg twice daily) during a 6-week run-in period. Patients were then randomly assigned to continued triple therapy or withdrawal of fluticasone in three steps over a 12-week period. The primary end point was the time to the first moderate or severe COPD exacerbation. Spirometric findings, health status, and dyspnea

NEJM2014

157. Stepping Down Therapy in COPD.

Stepping Down Therapy in COPD. Stepping down therapy in COPD. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 25196116 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add (...) to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2014 Oct 2;371(14):1340-1. doi: 10.1056/NEJMe1409219. Epub 2014 Sep 8. Stepping down therapy in COPD. 1 . 1 From the Department of Medicine, University of Pittsburgh, Pittsburgh. Comment on [N Engl J Med. 2014] PMID: 25196116 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substances Full Text Sources Medical Miscellaneous PubMed Commons 0 comments How to cite

NEJM2014

158. Performance of the BODE index in patients with alpha1-antitrypsin deficiency-related COPD

Performance of the BODE index in patients with alpha1-antitrypsin deficiency-related COPD 24525449 2014 07 01 2015 02 24 2014 07 01 1399-3003 44 1 2014 Jul The European respiratory journal Eur. Respir. J. Performance of the BODE index in patients with α1-antitrypsin deficiency-related COPD. 78-86 10.1183/09031936.00168113 The BODE (body mass index, airflow obstruction, dyspnoea and exercise capacity) index is used to decide on referral and transplantation of patients (...) with chronic obstructive pulmonary disease (COPD). The BODE index has not been validated in patients with α1-antitrypsin deficiency, who account for 15% of COPD patients undergoing lung transplantation. We sought to validate the BODE index in α1-antitrypsin deficiency-related COPD. We assessed the prognostic value of the BODE index in 191 patients followed from 2006 to 2012 in a French prospective cohort of patients with α1-antitrypsin deficiency. 20 patients died during follow-up and 22 underwent lung transplantation. Survival (95% CI

EvidenceUpdates2014

159. What are the benefits and risks of inhaled corticosteroids for COPD?

What are the benefits and risks of inhaled corticosteroids for COPD? What are the benefits and risks of inhaled corticosteroids for COPD? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What are the benefits and risks of inhaled corticosteroids for COPD? View/ Open Date 2014-05 Format Metadata Abstract Q: What (...) are the benefits and risks of inhaled corticosteroids for COPD? A: Inhaled corticosteroids (ICS), either alone or with a long-acting [beta] agonist (LABA), reduce the frequency of exacerbations of chronic obstructive pulmonary disease (COPD) and statistically, but not clinically, improve quality of life (QOL) (strength of recommendation [SOR]: B, meta-analyses of heterogeneous studies). However, ICS have no mortality benefit and don’t consistently improve forced expiratory volume in 1 second (FEV1) (SOR: B

Clinical Inquiries2014